[No standalone website (unbranded, no questionnaire)] A Study of Subjects With Psoriatic Arthritis to Investigate the Effectiveness of Adalimumab Introduction Compared With Methotrexate Dose Escalation (CONTROL)
Determine if a study site for this clinical trial is near you. Contact the study to apply.
Find a Study SiteCall center
Email address
Condition
Treatment type
Investigational product
Phase
Sponsor
ClinicalTrials.gov identifier
Study number
Get answers to your questions about clinical trials.
To assess early phase safety and tolerability of converting patients from approved oral, injectable or infusion RMS DMTs to siponimod (Mayzent). The results of this study will guide clinically relevant decisions related to the transition from frequently used RMS DMTs to siponimod (Mayzent) and provide clinically relevant data on safety and tolerability for healthcare providers who are considering converting patients from currently approved RMS DMT to siponimod (Mayzent).
You may be eligible to participate in the study if you meet the following criteria:
For a full list of inclusion/exclusion criteria, please visit ClinicalTrials.gov
Enter your ZIP code/Postal code/PIN code to locate study sites near you:
Determine if a study site for this clinical trial is near you. Contact the study to apply.
Find a Study SiteTo assess early phase safety and tolerability of converting patients from approved oral, ...